Drug Trial Radar · NCT04220190
RAPA-501 Therapy for ALS
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
41
Planned (sponsor's estimate)
Start
Jan 2, 2025
Primary completion
Jul 1, 2027
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- Rapa Therapeutics LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Massachusetts General Hospital
- First posted
- Jan 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
RAPA-501 Autologous T stem cellsBiological
Experimental: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)
Primary outcomes
What the sponsor says the trial is designed to measure.
- In the expansion cohort enrolling standard-risk pwALS, determine the feasibility and safety of the highest established safe dose of RAPA-501 (80 x 10^6 cells per infusion).Time frame: Through 30 Weeks On-Study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.